Skip to main content
Berry Genomics Co.,Ltd logo

Berry Genomics Co.,Ltd — Investor Relations & Filings

Ticker · 000710 ISIN · CNE000000PN7 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,009 across all filing types
Latest filing 2020-04-14 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000710

About Berry Genomics Co.,Ltd

https://www.berrygenomics.com

Berry Genomics Co.,Ltd. is a biotechnology enterprise specializing in clinical genomics and genetic testing services. The company focuses on the research, development, and commercialization of genomic technologies for clinical applications. Its core portfolio includes non-invasive prenatal testing (NIPT), utilizing high-throughput sequencing to screen for chromosomal abnormalities. Beyond reproductive health, the company provides genomic solutions for oncology diagnostics, including early cancer screening and companion diagnostics, as well as testing for hereditary diseases. Berry Genomics leverages advanced sequencing platforms and proprietary bioinformatics pipelines to deliver precision medicine tools to healthcare providers and research institutions. The company is recognized for its role in the clinical application of Next-Generation Sequencing (NGS) and its extensive genomic databases used to enhance diagnostic accuracy and therapeutic outcomes.

Recent filings

Filing Released Lang Actions
监事会对公司2019年度内部控制自我评价报告的意见
Regulatory Filings Classification · 95% confidence The document is an opinion from the Supervisory Board on the company's 2019 internal control self-evaluation report. It references regulatory guidelines on internal control and confirms the accuracy and completeness of the internal control report. The document is short (709 characters) and does not contain actual financial statements or detailed financial data. It is an opinion or commentary on an internal control report rather than the report itself. Therefore, it is best classified as a Regulatory Filing (RNS), which covers compliance documents and miscellaneous regulatory announcements that do not fit other categories.
2020-04-14 Chinese
独立董事关于2020年度日常关联交易预计的事前认可意见和独立意见
Regulatory Filings Classification · 95% confidence The document is a formal opinion from independent directors regarding the anticipated related party transactions for the fiscal year 2020. It references compliance with stock exchange listing rules and governance guidelines, and it provides pre-approval and independent opinions on these transactions. The document is relatively short (1057 characters) and does not contain financial statements or detailed financial data. It is not an annual report, audit report, or earnings release. Instead, it is a regulatory compliance document related to governance and related party transactions. Given the nature of the content and the absence of financial data, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-04-14 Chinese
2020年第一季度业绩预告
Earnings Release Classification · 95% confidence The document is a quarterly earnings forecast (业绩预告) for the first quarter of 2020, covering the period from January 1 to March 31, 2020. It provides estimated financial performance figures, including net profit and earnings per share, and explains the reasons for performance changes. It explicitly states that the data is unaudited and preliminary, with detailed financial data to be disclosed in the official quarterly report later. The document is short (1204 characters) and serves as an earnings preview rather than a full financial report. Therefore, it fits the category of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only. Q1 2020
2020-04-14 Chinese
2019年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制评价报告" which translates to "Internal Control Evaluation Report" for the year 2019. It discusses the company's internal control systems, evaluation scope, risk areas, and the effectiveness of internal controls over financial and non-financial reporting. The content is detailed and comprehensive, covering internal control frameworks, risk management, and compliance with regulatory standards. It does not present financial statements or earnings data but focuses on internal control evaluation results and related management responsibilities. This type of document aligns with an Audit Report / Information (AR) category, as it is a standalone report on internal controls and audit-related evaluation, not a full annual report or earnings release. The document length (8082 characters) and detailed content support classification as AR rather than a brief announcement or regulatory filing. FY 2019
2020-04-14 Chinese
2019年年度审计报告
Regulatory Filings
2020-04-14 Chinese
关于召开2019年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2019 Annual General Meeting (AGM) of Chengdu Berry Genomics Co., Ltd. It includes information about the meeting date, voting procedures, agenda items to be discussed and voted on, such as the 2019 annual report, financial statements, board and supervisory reports, profit distribution plan, internal control evaluation, appointment of auditors, and employee stock plans. The document does not contain the actual annual report or financial statements but rather serves as a formal notification and instructions for shareholders to participate in the AGM and vote on the proposals. The document length is 4432 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2020-04-14 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.